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Introduction
Protein–protein interactions (PPIs) are ubiquitous in nature and
play key roles in many cellular processes including apoptosis,
signal transduction, gene expression, and DNA repair and repli-
cation. It is not surprising that the inhibition of certain PPIs has
been hypothesised to have implications in many diseases, in-
cluding cancer.[1, 2] PPIs offer many potential targets for small-
molecule intervention in disease, but are a challenging and un-
derrepresented target class in modern drug discovery. PPI sites
bury greater surface areas than protein–ligand binding sites,
and are generally featureless by comparison,[3] often lacking
major concave binding pockets that naturally bind small mole-
cules.[4] PPI inhibitors consequently tend to bind in many small-
er pockets.[5] As a consequence of these inherent differences
between PPI sites and traditional targets, PPI inhibitors tend to
be larger, more hydrophobic, and form fewer hydrogen bonds
than the small-molecule ligands of enzymes.[6]
Despite these challenges, there have been a number of suc-
cesses in the development of PPI inhibitors, with various strat-
egies showing success against a diverse set of targets.[1] High-
throughput screening (HTS) is a common approach in modern
drug discovery, and was used successfully to develop the
Nutlin compounds, which bind MDM2 at the p53 binding
site.[7] However, HTS methodology has enjoyed limited success
against this target class.[8] For example, Fairbrother and co-
workers reported the failure of HTS in targeting the interaction
between the BIR3 domain of XIAP, and the partner protein
Smac; in this case, however, a screen of structure-based libra-
ries designed on the Smac binding epitope “AVPI” proved suc-
cessful.[8]
Fragment-based drug discovery (FBDD) has met with some
success in the field of PPI inhibitors. Briefly, in FBDD, low-mo-
lecular-weight compounds are screened at relatively high con-
centrations to identify weak, yet efficient binders.[9] Typically,
structural information regarding the fragment–protein complex
is then used to guide fragment “growth”—chemical elabora-
tion of the original hit—in order to establish additional interac-
tions. Different fragments may be found to bind simultaneous-
ly in adjacent pockets, in which case there may be an opportu-
nity for fragment “linking” to greatly improve potency, as was
reported by Petros et al. with a series of Bcl-2 inhibitors.[10] The
interaction between the anti-apoptotic Bcl-2 and BH3 proteins
is defined by a deep hydrophobic groove in Bcl-2 and has
been successfully targeted with compounds that have shown
antitumour activity in xenograft experiments,[11] and recently in
patients.[12] Further compounds have now begun to show
promise in clinical trials.[13, 14] A fragment screen against the
bacterial membrane-anchored protein ZipA identified frag-
ments that bind to the C-terminal region of ZipA. Compounds
were then developed and were shown to block the binding of
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an a-helix peptide from FtsZ.[15] Fesik and colleagues recently
used a fragment-based approach to develop small molecules
that prevent Sos binding to K-Ras by binding at a surface site
of K-Ras.[16] Despite these successes, identification of fragments
at PPI sites is not always possible. For example, fragmented
MDM2 compounds, which were screened as fragments, were
not found to show detectable activity unless they filled two
sub-pockets and were at the higher end of the typical molecu-
lar weight of fragments.[17] Also, Van Molle et al. reported being
unable to detect the binding of fragments dissected from
high-potency compounds against von Hippel–Lindau pro-
tein.[18]
In this work we targeted the protein–protein interaction be-
tween RAD51 and the tumour suppressor protein, BRCA2.
RAD51 is a recombinase involved in the homology-directed
repair of DNA double-strand breaks, forming an active filament
with single-strand DNA in an ATP-hydrolysis-dependent pro-
cess.[19] Structurally, its interaction with BRCA2 is mediated by
eight BRC repeats that are characterised by a common FxxA
motif (Figure 1 A).[20] In addition, the FxxA sequence motif
occurs in the N-terminal linker region of RAD51, enabling it to
self-oligomerise through interaction with this region to form
RAD51 filaments (Figure 1 B). The FxxA oligomerisation motif
of RAD51 is highly conserved across several species,[21] and six
of the eight BRC repeats conserve the same motif across sever-
al mammalian BRCA2 proteins.[20] The structural basis of this
FxxA motif was elucidated by Pellegrini et al. , who solved the
X-ray crystal structure of truncated human RAD51 in complex
with the fourth BRC repeat (BRC4) from human BRCA2.[21] The
structure revealed FxxA as part of a b-hairpin across the sur-
face of RAD51, with Phe 1524 of BRC4 in a surface pocket on
RAD51, and Ala 1527 contacting the surface in a much shallow-
er pocket, across the central b-sheet of RAD51. As BRCA2 is in-
volved in localisation of RAD51 and formation of a nucleopro-
tein filament on DNA at sites of double-strand breaks, we hy-
pothesise that disrupting the interaction between RAD51 fila-
ment protomers and between RAD51 and BRCA2 is a valid
strategy to increase the susceptibility of tumour cells to radia-
tion and DNA-damaging agents.[22] Therefore, the development
of a small molecule that disrupts these interactions by binding
at the common FxxA binding site is of interest both as a chemi-
cal tool and as a potential therapeutic compound.
We previously published fragment-screening results using
a humanised RAD51 surrogate from Pyrococcus furiosus, which
we refer to as HumRADA2 (previously referred to as MAYSAM
RadA).[23] In this surrogate protein, the N-terminal domain with
the oligomerisation sequence was removed to monomerise
the protein and expose the FxxA binding site for screening,
and six surface residues were mutated around the Phe pocket
in order to humanise the protein in this region. The tetrapep-
tide Ac-FHTA-NH2, derived from the BRC4 peptide, was found
to have a KD value of 250 mm, and the crystal structure in com-
plex with humanised RadA was solved (Figure 1 D,E). A set of
fragments that bind at the PPI interface in the Phe pocket of
the FxxA motif were also identified, including indazole (KD =
1000 mm), l-tryptophan methyl ester 1 (KD = 570 mm, Fig-
ure 1 F), and 4-methyl ester indole (KD = 1300 mm).
Results and Discussion
Herein we present the development of these frag-
ment hits from millimolar to low-micromolar poten-
cy. Initially, small modifications were made to 1,
which led to only small changes in potency (Table 1
compounds 2–4). Compounds with more significant,
yet still relatively modest modifications were then
synthesised and tested by isothermal titration calo-
rimetry (ITC) (Table 1). The benzyl ester 5 b showed
a small increase in potency, KD = 200 mm, relative to
the parent fragment 1. Extending the carbon chain
by another atom gave strikingly better potency:
compound 5 c, which at 35 mm, exhibited an approxi-
mate 10-fold improvement over the parent fragment
1. An investigation of the length of the ester carbon
chain revealed that the ethyl linker is optimal ; both
the phenyl ester 5 a and the phenpropyl ester 5 d
showed poorer potency (Table 1). An SAR study fo-
cused around the phenyl group of compound 5 c
identified substituents that had only a moderate
effect on potency and those that did not bind (KD>
200 mm). Changing the ester group to an amide led
to a large decrease in affinity (Table 1, compound
5 e). A range of substituents are tolerated on the
phenyl ring, with methyl, fluoro, and hydroxy groups
(Table 1, compounds 5 f–j), and no significant
change in KD was observed. However if 4-bromo and
Figure 1. A)–C) Cartoon representation of RAD51 binding sites. In addition to an ATP
binding site and a BRC repeat helix binding site (“Velcro” region), a surface binding
pocket (green) binds the FxxA epitope of the BRC repeats of BRCA2 (A, blue) and the
self-oligomerisation peptide of RAD51 (B, orange). The Ac-FHTA-NH2 tetrapeptide is indi-
cated for clarity (C, red). D) Crystal structure of Ac-FHTA-NH2 (red) bound to RAD51 (PDB
code 4B3B). E) Highlight showing surface pocket of RAD51; the contacting surface is rep-
resented in green. F) l-Methyl ester tryptophan 1 fragment previously identified that
binds in the Phe pocket of HumRADA2 (PDB code 4B2I).[21]
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4-methoxy groups were intro-
duced to the phenyl ring, there
was a significant decrease in af-
finity, presumably due to a steric
clash with the protein at the
para position (Table 1, com-
pounds 5 k and 5 l). Replacing
the phenyl ring with cyclohexyl
or indole rings was also tolerated
(Table 1, compounds 5 m and
5 n).
Further modification of com-
pound 5 c also focused attention
on the amino group. Modifica-
tion with acetyl had no signifi-
cant effect on affinity (Table 1,
compound 6 b). However, the in-
troduction of benzoyl onto the
amino group led to a significant
increase in affinity: KD = 3 mm
(Table 1, compound 6 a). A meta-
nitrophenyl substituent, a cyclo-
hexyl amide, and a phenethyl
amide all failed to give detecta-
ble activity (Table 1, compounds
6 c–e).
Inspired by the indole scaffold
from tryptophan and other frag-
ments previously reported to
bind in this pocket,[23] we devel-
oped a series of sulfonamide de-
rivatives of tryptamine. We rea-
soned that the indole motif
would anchor in the Phe pocket,
and a sulfonamide linkage with
hydrogen bond acceptors and
donors would have the ability to
form hydrogen bonds to proxi-
mal side chains around the Phe
pocket such as Gln 217 and the
backbone of Tyr 202, to which
the FHTA peptide also forms hy-
drogen bonds. Initially the
phenyl sulfonamide 7 a and the
benzyl sulfonamide 7 b were syn-
thesised and tested by ITC. Inter-
estingly, only the phenyl sulfona-
mide 7 a exhibited evidence of
binding, with a KD value of
28 mm, indicating specific re-
quirement for a directly attached
phenyl ring. No activity was de-
tectable for the benzyl substitu-
ent 7 b or for the methyl sulfona-
mide compound 7 i. The SAR
around the phenyl ring was ex-
plored with compounds 7 c–h,
Table 1. SAR for tryptophan ester series binding to HumRADA2 (ITC).
Compd R1 R2 LE[a] LLE[b] KD [mm]
[c]
1 H 0.28 1.9 570[23]
2 H 0.24 2.2 150024
3 0.22 2.0 81019
4 0.22 2.6 89015
5 a H 0.24 0.7 1905
5 b H 0.23 0.7 2008
5 c H 0.26 1.1 354
5 d H 0.22 0.02 1607
5 e H – – >200
5 f H 0.26 1.1 255
5 g H 0.26 1.5 2712
5 h H 0.26 0.7 309
5 i H 0.26 0.7 307
5 j H 0.26 0.8 224
5 k H – – >200
5 l H – – >200
5 m H 0.27 0.8 289
5 n H 0.23 1.0 359
6 a 0.24 0.5 31
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and the results are listed in Table 2. The introduction of a bro-
mine atom at the 4-position of the phenyl ring led to a de-
crease in affinity to 92 mm ; however, if the bromine substitu-
tion was at the 2-position, the affinity increased to 3.1 mm
(Table 2, compounds 7 c and 7 d). The inclusion of NO2 or NH2
groups at the 3-position had no significant effect on affinity
(Table 2, compounds 7 e and 7 f). Interestingly, if 4-methoxy
was included on the phenyl ring, a decrease in affinity was ob-
served, but if this was replaced with the structurally similar
benzodihydrofuran (Table 2, compounds 7 g and 7 h) the affini-
ty was recovered to 34 mm. Unsurprisingly, replacing the
phenyl ring with a thiophene ring, which is sometimes used as
a phenyl isostere, gave a KD value similar to that of the phenyl
group (Table 2, compound 7 j). We then explored SAR around
substituted thiophenes: compounds 7 k–p. Clear improve-
ments in potency were observed with benzothiophene
(Table 2, compound 7 p, KD = 1.6 mm) and halogenated
thiophenes, most notably thiophene 7 m, which has a KD value
of 1.3 mm. We also explored a selection of more polar five-
membered heterocycles, a substituted isoxazole 7 q, a furan
7 r, and a methylimidazole 7 s. Whilst the furan possessed
similar potency to the phenyl compound 7 a, the isoxazole
showed a drop in potency to 110 mm. The imidazole 7 s
was the amongst the weakest binding of all compounds
(KD = 420 mm). Taken together, the SAR seems largely
driven by a hydrophobic interaction with the substituent on
the sulfonamide; para substituents on phenyl rings are
not well tolerated relative to ortho substituents, suggesting
a steric clash or unfavourable interaction on the protein
surface in a manner similar to that observed for the trypto-
phan ester series. Substituents on the thiophene scaffold
yielded a number of potent compounds; however, it appears
that hydrophobic groups appear to give the largest increases
in potency. The more polar five-membered heterocycles
showed decreased potency rela-
tive to the unsubstituted phenyl
ring.
Unfortunately, attempts to
crystallise and solve the struc-
tures of the more potent sulfo-
namide compounds and trypto-
phan ester compounds in com-
plex with the target protein
were unsuccessful. Often poor
electron density for only a single
ring was observed in the Phe
pocket, but could not be unam-
biguously assigned to either
ring of the molecule. It is possi-
ble that there is some specific
molecular recognition in the
pocket, but disorganisation in
the binding modes as the mole-
cule emerges from the Phe
pocket, providing hydrophobic
interactions with the protein
surface. Therefore, in X-ray crys-
tallography we might see part of a ligand bound in the Phe
pocket, but a superposition of binding modes outside the
pocket would render this part of the ligand invisible. Hence,
the location of the binding site of compound 5 c was investi-
gated by ITC experiments (Figure 2). Binding of 5 c could be
detected directly against the HumRADA2 protein with
a humanised FxxA binding site (KD = 35 mm), but not against
the unhumanised wild-type RadA protein (Figure 2 A). The im-
portance of the humanising mutations around the Phe pocket
to binding is highly suggestive of 5 c interacting at this site.
Competitive ITC experiments also implicated the FxxA binding
site (Figure 2 B). Briefly, titrations of tetrapeptide Ac-FHTA-NH2
(KD = 250 mm), the wild-type RadA oligomerisation peptide
(KD = 7.0 mm), and ATP (KD = 2.5 mm) were performed individual-
ly against apo protein to measure their respective KD values
(top row titrations, Figure 2 B). The KD measurement of each
ligand was then repeated, but in the presence of 200 mm 5 c
(bottom row titrations, Figure 2 B). As expected for an FxxA
site binder in this system, the binding of ATP was not affected
by pre-incubation of the protein with 5 c, but 5 c competes
with and blocks the binding of both the self-oligomerisation
peptide and the Ac-FHTA-NH2 tetrapeptide. Taken together,
these experiments provide strong evidence that the FHTA in-
teraction site is the specific binding site of 5 c. Analogous com-
petitive ITC experiments with 7 m also demonstrated blockage
of the binding to humanised RAD51 of the oligomerisation
peptide but not ATP, consistent with specific binding at the
FHTA binding site (data not shown).
It has previously been observed with thrombin inhibitors
that substituting a terminal cyclopentyl ring for a cyclohexyl
group in the S3/S4 specificity pocket can have marked changes
on the binding thermodynamics and the electron density ob-
served in X-ray crystallography.[24] The binding of the cyclopen-
tyl compound was enthalpically driven, and the cyclopentyl
Table 1. (Continued)
Compd R1 R2 LE[a] LLE[b] KD [mm]
[c]
6 b 0.25 1.5 181
6 c – – >200
6 d – – >200
6 e – – >200
[a] Ligand efficiency (kcal mol1 per heavy atom). [b] LLE = pKDclog P ; clog P was calculated with Instant
JChem (ChemAxon). [c] Estimated errors in KD are given, generated by fitting a single-site binding model
(Origin software version 7.0552).
ChemMedChem 2015, 10, 296 – 303 www.chemmedchem.org  2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim299
Full Papers
group was clearly observed bound to the protein by X-ray
crystallography. In contrast, the cyclohexyl compound, which
had the same KD value, was driven to bind by favourable en-
tropic factors; the cyclohexyl appendage was disordered and
could not be observed crystallographically. For this reason,
and the lack of clear electron density for our compounds, we
analysed the entropic and enthalpic contributions to our de-
veloped series in greater detail. Comparison of the binding
thermodynamics of the original fragment 1 and the modified
fragments, compounds 2–4, is shown in Figure 3 (Table S1 in
Supporting Information). The binding of the fragments is en-
thalpically driven, overcoming an entropic penalty of binding
of ~2 kcal mol1. The binding of the oligomerisation peptide,
which binds with KD = 7.0 mm, is almost entirely driven by fa-
vourable enthalpic contributions. However, for the representa-
tive lead series compounds 5 c, 6 a, and 7 m, it is clear that in-
creased potency has largely been achieved by optimisation of
favourable entropic contributions. This switch in binding from
enthalpy-driven fragments to an entropy-driven series is no
doubt in part due to the hydrophobic nature of the attached
groups. The favourable entropic component of binding of the
lead series may reflect a disordered binding mode and may
explain the difficulties in obtaining a crystal structure in com-
plex with the protein. In retrospect, we can speculate that in-
troducing hydrogen bond acceptors and donors to both rings
might anchor both ends of the molecule, fixing a compound
into an ordered binding mode. Although not necessarily im-
parting potency, presumably such a molecule would be more
amenable to X-ray crystallography.
We have elaborated initial fragment hits that bind in a small
surface pocket of a humanised RAD51 construct and have in-
creased the potency by approximately 500-fold to ~1 mm.
Drug development is a multidimensional optimisation prob-
lem, however, and affinity for the target is not the only consid-
eration. The utility of ligand efficiency metrics in drug discov-
ery to assess the relative importance of affinity, log P, and mo-
lecular weight has recently been reviewed.[25] Ligand efficiency
(LE) is defined as the free energy of binding in kcal mol1 per
non-hydrogen atom. An examination of the LEs of the com-
pounds in each series reveals some interesting differences. In
the tryptophan ester series, the starting fragment 1 (KD =
570 mm) has an LE of 0.28. This value is slightly below the
value of 0.3 kcal mol1 per heavy atom, which is commonly ac-
cepted as a reasonable threshold for non-PPI targets; however,
it has previously been noted that inhibitors of PPIs tend to
have a lower LE of 0.24.[26] The developed phenethyl ester 5 c
(KD = 35 mm) had an LE of 0.26, which fell subsequently to 0.24
for 6 a (KD = 3 mm), the most potent compound in this series.
Conversely, several of the more potent compounds in the sul-
fonamide series possessed an improved LE, especially the
most potent compound 7 m, which had an LE of 0.36. This is
a desirable achievement for any FBDD programme and even
more impressive for small molecules that bind at a PPI site.
Lipophilic ligand efficiency (LLE) is a ligand efficiency metric
that penalises molecules which are highly lipophilic and is de-
fined as the pIC50 (or pKD) minus clog P.
[27] The higher the LLE
value, the more potency is generated for a given lipophilicity.
Table 2. SAR for substituted tryptamine series binding to HumRADA2
(ITC).
Compd R LE[a] LLE[b] KD [mm]
[c]
7 a 0.30 1.6 286
7 b – – >200
7 c 0.25 0.4 9222
7 d 0.34 1.8 3.10.1
7 e 0.27 1.9 184
7 f 0.28 2.4 316
7 g 0.23 1.2 12010
7 h 0.25 1.7 3412
7 i – – >200
7 j 0.33 1.9 166
7 k 0.32 1.2 101
7 l 0.32 1.3 131
7 m 0.36 1.5 1.30.1
7 n 0.33 0.6 2.30.4
7 o 0.27 0.4 6729
7 p 0.33 1.8 1.60.6
7 q 0.25 2.4 11012
7 r 0.32 2.6 182
7 s 0.22 1.8 42074
[a] Ligand efficiency (kcal mol1 per heavy atom). [b] LLE = pKDclog P ;
clog P was calculated with Instant JChem (ChemAxon). [c] Estimated errors
in KD are given, generated by fitting a single-site binding model (Origin
software version 7.0552).
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Although the potency of the compounds was not optimised
with LLE in mind, it is interesting to retrospectively examine
the LLEs. It has been suggested that optimised drug molecules
should aim to possess an LLE of 5–7, although absolute values
depend on the method used to calculate clog P. For the trypto-
phan series, the LLE generally drops as the compounds are
progressed from fragment 1 (LLE = 1.9), to 6 a (LLE = 0.5) for
example. The situation is a little better for the sulfonamide
series ; the most potent compound 7 m (KD = 1.3 mm) has an
LLE of 1.5. Compound 7 p, which
has a similar KD value of 1.6 mm,
is less lipophilic than 7 m and
has a marginally improved LLE
of 1.8. Taken together, the met-
rics indicate that although the
LE and LLE fall for the trypto-
phan series, the LLE can be
maintained in the sulfonamide
series whilst improving potency
and actually increasing LE, sug-
gesting the sulfonamide series is
more attractive in terms of their
suitability toward development.
Conclusions
Although we were unable to
obtain X-ray crystal structures
for our best compounds bound
to the protein, direct and com-
petitive ITC experiments strongly
implicate the FxxA binding
region as the most probable
binding site. A retrospective
analysis of the thermodynamics
of ligand binding reveals
a strong entropic component,
suggesting that the increase in
log P of the compounds caused
the potency to increase through
hydrophobic interactions with
the protein surface. With a lack
of hydrogen bonds that might
be thought to specifically orient
a molecule, we hypothesise that
a multitude of binding poses for
the lipophilic moieties of the
lead molecules may be superim-
posing in X-ray crystallography
and causing a disappearance of
ligand electron density. There-
fore, a future strategy for elabo-
ration of these compounds will
involve introducing a balance of
lipophilicity and polar interac-
tions, as well as decreasing log P.
We are currently developing
functional assays with these compounds which will be report-
ed at a later date.
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Figure 2. A) Structure of compound 5 c, and binding directly to HumRADA2 (left, KD = 35 mm) and showing no
binding to the wild-type RadA (right). B) Competitive ITC experiments to HumRADA2 indicate the binding site of
5 c. Top row: ITC experiments in the absence of 5 c determined the KD values of Ac-FHTA-NH2, the RadA oligomeri-
sation peptide, and ATP to be 290, 7.0, and 2.5 mm, respectively. Bottom row: ITC of Ac-FHTA-NH2, RadA oligomeri-
sation peptide, and ATP in the presence of 200 mm 5 c shows competition with the FxxA binding site, but not the
ATP binding site.
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